Literature DB >> 15819690

Rituximab for pure red cell aplasia after ABO-mismatched allogeneic peripheral blood progenitor cell transplantation.

Federica Sorà, Silvia De Matteis, Nicola Piccirillo, Patrizia Chiusolo, Luca Laurenti, Rossana Putzulu, Giuseppe Leone, Simona Sica.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15819690     DOI： 10.1111/j.0041-1132.2005.00445.x

Source DB:  PubMed          Journal:  Transfusion        ISSN： 0041-1132            Impact factor:   3.157


× No keyword cloud information.
  4 in total

Review 1.  The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.

Authors:  Elizabeth Naparstek
Journal:  Curr Hematol Malig Rep       Date:  2006-12       Impact factor: 3.952

2.  A diagnostic dilemma in stem cell transplantation for beta-thalassemia major: progressive loss of take or pure red cell aplasia?

Authors:  Giuseppe Visani; Moira Lucesole; Giuliana Leopardi; Barbara Guiducci; Claudio Giardini; Alessandro Isidori
Journal:  Int J Hematol       Date:  2007-12       Impact factor: 2.490

Review 3.  Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.

Authors:  Javier Marco-Ayala; Inés Gómez-Seguí; Guillermo Sanz; Pilar Solves
Journal:  Bone Marrow Transplant       Date:  2020-11-14       Impact factor: 5.483

4.  Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins.

Authors:  Georg Stussi; Jörg Halter; Eveline Bucheli; Piero V Valli; Lutz Seebach; Jürg Gmür; Alois Gratwohl; Urs Schanz; Jakob R Passweg; Jörg D Seebach
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.